Breaking News

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs

Initiated Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich’s Ataxia; Actively Preparing for Commercial Launch Updated Cash Guidance – Sufficient to Fund Operations Through End of 2024 Conference Call with Management on February 28, 2022, at 8:30 A.M. ET PLANO, Texas, February 28, 2022–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the […]